For the first time in Kazakhstan, an analysis for markers of liver fibrosis has been introduced in the OLYMP CDL branches

OLYMP CDL is the first and only laboratory in Kazakhstan that has introduced the determination of liver fibrosis markers using the ELF test performed on Siemens analyzers.

In a number of countries, the ELF test has already been introduced into clinical practice, and its impact on the quality of patient diagnostics has been appreciated. The ability to use a routine blood count to accurately identify patients with serious liver disease is of great help in making a diagnosis and prescribing therapeutic measures accordingly.

The ELF test is not a substitute for liver biopsy in the detailed evaluation of inflammatory and structural pathological changes. However, it can be used to prioritize patient examinations, the severity of fibrosis in patients who are unwilling or unable to undergo a biopsy, and in addition to biopsy, minimizing histological errors.

Once diagnosed with chronic liver disease, most patients undergo some course of treatment with long-term follow-up. For the vast majority of patients, further repeat biopsy is unacceptable, but additional knowledge about the severity of the fibrosis, its progression or regression is of particular value to both the patient and the doctor. The ELF test will provide this information through a simple blood test that can be repeated at short intervals.